Marion Kiechle Selected Research

Plasminogen Activator Inhibitor 1

10/2016	Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers.
8/2013	Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer.
3/2007	Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
12/2004	Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
3/2003	Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
8/2002	Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
8/2002	Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marion Kiechle Research Topics

Disease

73	Neoplasms (Cancer) 11/2023 - 08/2002
71	Breast Neoplasms (Breast Cancer) 05/2024 - 08/2002
19	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 03/2007
12	Triple Negative Breast Neoplasms 01/2023 - 10/2016
8	Neoplasm Metastasis (Metastasis) 04/2024 - 03/2004
8	Familial Breast Cancer 06/2011 - 08/2006
6	Carcinogenesis 09/2022 - 03/2007
6	Residual Neoplasm 07/2019 - 03/2007
5	Fatigue 11/2023 - 01/2016
4	Leukopenia 12/2020 - 01/2010
4	Febrile Neutropenia 08/2013 - 04/2006
3	Dihydropyrimidine Dehydrogenase Deficiency 06/2011 - 10/2007
2	Sepsis (Septicemia) 01/2022 - 01/2016
2	Obesity 04/2021 - 12/2017
2	Ascites 07/2019 - 03/2007
2	Vomiting 04/2017 - 06/2016
2	Nausea 04/2017 - 06/2016
2	Hypothermia 04/2005 - 08/2004
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 10/2023
1	Endometrial Neoplasms (Endometrial Cancer) 07/2023
1	Microsatellite Instability 07/2023
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2022

Drug/Important Bio-Agent (IBA)

23	Biomarkers (Surrogate Marker)IBA 05/2024 - 04/2009
15	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2005
13	Messenger RNA (mRNA)IBA 09/2022 - 05/2005
13	AnthracyclinesIBA 10/2021 - 04/2006
12	Peptide Hydrolases (Proteases)FDA Link 09/2022 - 04/2012
11	Kallikreins (Kallikrein)IBA 09/2022 - 04/2012
10	Hormones (Hormone)IBA 05/2024 - 05/2005
10	Fluorouracil (Carac)FDA LinkGeneric 12/2020 - 02/2003
8	AntigensIBA 10/2020 - 08/2002
8	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2017 - 08/2002
7	taxaneIBA 04/2017 - 01/2008
7	Plasminogen Activator Inhibitor 1IBA 10/2016 - 08/2002
6	Docetaxel (Taxotere)FDA Link 12/2020 - 01/2010
6	Tissue ExtractsIBA 01/2016 - 08/2002
5	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 06/2011 - 12/2003
4	Tumor Biomarkers (Tumor Markers)IBA 08/2023 - 12/2004
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2022 - 04/2006
4	PlatinumIBA 10/2022 - 03/2007
4	ChemokinesIBA 09/2022 - 02/2012
4	SteroidsIBA 01/2017 - 05/2005
4	EnzymesIBA 10/2007 - 08/2002
3	B7-H1 AntigenIBA 01/2023 - 03/2021
3	Indicators and Reagents (Reagents)IBA 01/2022 - 11/2009
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2020 - 11/2009
3	Epirubicin (Ellence)FDA LinkGeneric 12/2020 - 06/2016
3	Formaldehyde (Formol)FDA Link 12/2018 - 01/2017
3	ParaffinIBA 12/2018 - 01/2017
3	Transcription Factors (Transcription Factor)IBA 11/2018 - 11/2006
3	Serine Proteases (Serine Protease)IBA 06/2018 - 01/2013
3	Plasminogen InactivatorsIBA 12/2011 - 08/2002
3	Tamoxifen FDA LinkGeneric 04/2009 - 05/2005
3	Amino Acids FDA Link 02/2007 - 08/2006
2	Phenobarbital (Luminal)FDA Link 05/2024 - 02/2020
2	Epithelial Cell Adhesion MoleculeIBA 08/2023 - 10/2012
2	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2022
2	CytokinesIBA 09/2022 - 06/2017
2	Progesterone FDA LinkGeneric 12/2021 - 01/2017
2	Nicotine FDA Link 01/2021 - 12/2017
2	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2017
2	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2009
2	rat KLK7 proteinIBA 10/2020 - 01/2014
2	Vitamin D FDA LinkGeneric 01/2018 - 03/2017
2	hydroxide ionIBA 01/2018 - 03/2017
2	LigandsIBA 06/2017 - 02/2012
2	Tissue Kallikreins (Tissue Kallikrein)IBA 01/2017 - 03/2007
2	Plasminogen Activators (Plasminogen Activator)IBA 01/2017 - 08/2002
2	Estrogens (Estrogen)FDA Link 01/2017 - 11/2006
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2016 - 06/2011
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2016 - 06/2011
2	Celecoxib (Celebrex)FDA Link 01/2016 - 02/2012
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2016 - 02/2012
2	Indomethacin (Indometacin)FDA LinkGeneric 01/2016 - 02/2012
2	Dinoprostone (PGE2)FDA Link 01/2016 - 02/2012
2	Taxoids (Taxanes)IBA 04/2012 - 04/2006
2	Estrogen ReceptorsIBA 12/2011 - 11/2006
2	Biological FactorsIBA 11/2011 - 03/2004
2	RNA (Ribonucleic Acid)IBA 11/2009 - 04/2009
2	A Kinase Anchor ProteinsIBA 03/2008 - 02/2007
2	Capecitabine (Xeloda)FDA Link 01/2008 - 08/2005
2	ImmunosorbentsIBA 03/2003 - 08/2002
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2024
1	LipidsIBA 08/2023
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 08/2023

Therapy/Procedure

46	Therapeutics 04/2024 - 08/2002
32	Drug Therapy (Chemotherapy) 05/2024 - 11/2004
12	Adjuvant Chemotherapy 05/2024 - 08/2002
3	Neoadjuvant Therapy 11/2023 - 01/2009
3	Mediterranean Diet 10/2023 - 01/2020
3	Complementary Therapies (Alternative Medicine) 08/2020 - 09/2018
2	Mammaplasty (Breast Reconstruction) 08/2023 - 04/2022
2	Combination Drug Therapy (Combination Chemotherapy) 01/2017 - 01/2010
2	Catheters 01/2016 - 11/2009
2	Lymph Node Excision (Lymph Node Dissection) 05/2014 - 09/2003
2	Segmental Mastectomy (Lumpectomy) 09/2012 - 05/2006
2	Anesthesia 05/2006 - 08/2004
1	Brachytherapy 01/2023
1	Chemoradiotherapy 01/2023